CLINICAL BRIEFINGS: #Precisionmedicine improves outcomes in metastatic #breastcancer @Nature https://t.co/WmjoC4c3LK #PM101 #ESCAT #cancer #clinicaltrials #Genomics to select treatment for patients w/ #metastaticbreastcancer https://t.co/R4aNWiLYO9 NB: h
RT @Annals_Oncology: Many presentations at #ESMO21 cited the @myESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Find mo…
これって2021年版（2022年版？）は出ないのかしら？
RT @myESMO: And find out more in articles below about The ESMO-Magnitude of Clinical Benefit Scale (#ESMO-MCBS) a dynamic tool to assist in…
RT @myESMO: And find out more in articles below about The ESMO-Magnitude of Clinical Benefit Scale (#ESMO-MCBS) a dynamic tool to assist in…
RT @myESMO: And find out more in articles below about The ESMO-Magnitude of Clinical Benefit Scale (#ESMO-MCBS) a dynamic tool to assist in…
RT @myESMO: And find out more in articles below about The ESMO-Magnitude of Clinical Benefit Scale (#ESMO-MCBS) a dynamic tool to assist in…
RT @myESMO: And find out more in articles below about The ESMO-Magnitude of Clinical Benefit Scale (#ESMO-MCBS) a dynamic tool to assist in…
RT @myESMO: And find out more in articles below about The ESMO-Magnitude of Clinical Benefit Scale (#ESMO-MCBS) a dynamic tool to assist in…
RT @myESMO: And find out more in articles below about The ESMO-Magnitude of Clinical Benefit Scale (#ESMO-MCBS) a dynamic tool to assist in…
RT @myESMO: And find out more in articles below about The ESMO-Magnitude of Clinical Benefit Scale (#ESMO-MCBS) a dynamic tool to assist in…
RT @myESMO: And find out more in articles below about The ESMO-Magnitude of Clinical Benefit Scale (#ESMO-MCBS) a dynamic tool to assist in…
And find out more in articles below about The ESMO-Magnitude of Clinical Benefit Scale (#ESMO-MCBS) a dynamic tool to assist in the prioritisation of medicines in #cancercare: ➡️https://t.co/Lajf3y5LdU ➡️https://t.co/5909OfyflD ➡️https://t.co/8vElWrHDHk ➡️
@BenWestphalen @brunolarvol @darioT_ @FDAOncology @OncoAlert @Alfdoc2 @APassaroMD So it sounds like Tier I on this framework : https://t.co/1A7kLMzEIM
@UmutDisel @BenWestphalen A ESMO Scale of Clinical Actionability for molecular Targets (ESCAT) defines six levels of clinical evidence for molecular targets according to the implications for patient management .MEKi in MAP2K1 is not yet Tier I https://t.co
A framework to rank genomic alterations as targets for cancer #PrecisionMedicine : the @myESMO Scale for Clinical Actionability of molecular Targets (ESCAT) [Aug 21, 2018] Mateo et al. @Annals_Oncology https://t.co/woSwf15iFl
A framework to rank genomic alterations as targets for cancer #PrecisionMedicine : the @myESMO Scale for Clinical Actionability of molecular Targets (ESCAT) [Aug 21, 2018] Mateo et al. @Annals_Oncology https://t.co/woSwf15iFl
New from #OfficialNIHR https://t.co/YHSqGnWxsd A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
New from #wellcometrust https://t.co/YHSqGnWxsd A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
New from #The_MRC https://t.co/YHSqGnWxsd A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
New from #CR_UK https://t.co/YHSqGnWxsd A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
RT @VHIO: An @Annals_Oncology article first-authored by VHIO's @quimmateo proposes a classification system that offers a common language fo…
RT @VHIO: An @Annals_Oncology article first-authored by VHIO's @quimmateo proposes a classification system that offers a common language fo…
An @Annals_Oncology article first-authored by VHIO's @quimmateo proposes a classification system that offers a common language for all the relevant stakeholders in #cancer medicine and drug development. https://t.co/jhl6WEcz3w
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @ChristianRolfo: Very useful tool. Another scale we use is oncoKB from @sloan_kettering. We published our experience in molecular tumor…
RT @ChristianRolfo: Very useful tool. Another scale we use is oncoKB from @sloan_kettering. We published our experience in molecular tumor…
RT @ChristianRolfo: Very useful tool. Another scale we use is oncoKB from @sloan_kettering. We published our experience in molecular tumor…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @ChristianRolfo: Very useful tool. Another scale we use is oncoKB from @sloan_kettering. We published our experience in molecular tumor…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
Working on to be on the same page #forabetterworld in #healthcare Genomic alterations-based decisions might be very useful if there is stardarization. @myESMO #Precisionmedicine #genomics #biomarkers #sequencing #oncology #Cancers
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @ChristianRolfo: Very useful tool. Another scale we use is oncoKB from @sloan_kettering. We published our experience in molecular tumor…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @ChristianRolfo: Very useful tool. Another scale we use is oncoKB from @sloan_kettering. We published our experience in molecular tumor…
RT @ChristianRolfo: Very useful tool. Another scale we use is oncoKB from @sloan_kettering. We published our experience in molecular tumor…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @ChristianRolfo: Very useful tool. Another scale we use is oncoKB from @sloan_kettering. We published our experience in molecular tumor…
RT @ChristianRolfo: Very useful tool. Another scale we use is oncoKB from @sloan_kettering. We published our experience in molecular tumor…
Very useful tool. Another scale we use is oncoKB from @sloan_kettering. We published our experience in molecular tumor board using the levels of evidence in @ESMO_Open https://t.co/R4UWWPcpbB #Oncoalert @myESMO
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
RT @Annals_Oncology: A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actio…
A framework to rank genomic alterations as targets for cancer precision medicine: the @myESMO Scale for Clinical Actionability of molecular Targets (ESCAT) https://t.co/1fuwSm375y
framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) 유럽종양내과학회의 분자 표적에 대한 임상적 유용성 단계의 정의. #5abstracts_a_day https://t.co/JTyq3vYx4Y
RT @mtmdphd: A framework to rank genomic alterations as targets for cancer #PrecisionMedicine : the @myESMO Scale for Clinical Actionabilit…
RT @mtmdphd: A framework to rank genomic alterations as targets for cancer #PrecisionMedicine : the @myESMO Scale for Clinical Actionabilit…
A framework to rank genomic alterations as targets for cancer #PrecisionMedicine : the @myESMO Scale for Clinical Actionability of molecular Targets (ESCAT) [Aug 21, 2018] Mateo et al. @Annals_Oncology https://t.co/woSwf15iFl HT @antonyruggeri
RT @mtmdphd: A framework to rank genomic alterations as targets for cancer #PrecisionMedicine : the @myESMO Scale for Clinical Actionabilit…
A framework to rank genomic alterations as targets for cancer #PrecisionMedicine : the @myESMO Scale for Clinical Actionability of molecular Targets (ESCAT) [Aug 21, 2018] Mateo et al. @Annals_Oncology https://t.co/woSwf15iFl HT
RT @VivekSubbiah: Framework to rank genomic alterations as targets for cancer #PrecisionMedicine: @myESMO Scale 4 Clinical Actionability…
RT @VivekSubbiah: Framework to rank genomic alterations as targets for cancer #PrecisionMedicine: @myESMO Scale 4 Clinical Actionability…
RT @VivekSubbiah: Framework to rank genomic alterations as targets for cancer #PrecisionMedicine: @myESMO Scale 4 Clinical Actionability…
RT @VivekSubbiah: Framework to rank genomic alterations as targets for cancer #PrecisionMedicine: @myESMO Scale 4 Clinical Actionability…
RT @VivekSubbiah: Framework to rank genomic alterations as targets for cancer #PrecisionMedicine: @myESMO Scale 4 Clinical Actionability…
RT @VivekSubbiah: Framework to rank genomic alterations as targets for cancer #PrecisionMedicine: @myESMO Scale 4 Clinical Actionability…
RT @VivekSubbiah: Framework to rank genomic alterations as targets for cancer #PrecisionMedicine: @myESMO Scale 4 Clinical Actionability…
RT @VivekSubbiah: Framework to rank genomic alterations as targets for cancer #PrecisionMedicine: @myESMO Scale 4 Clinical Actionability…
Framework to rank genomic alterations as targets for cancer #PrecisionMedicine: @myESMO Scale 4 Clinical Actionability of molecular Targets @Annals_Oncology @FAndreMD 👉We need to adopt this @asco ! https://t.co/Tqyp0Wdton
RT @FAndreMD: ESMO released a scale to interpret genomic alterations found by NGS in daily practice or access programs. this should decreas…
RT @Annals_Oncology: The @myESMO Scale for Clinical Actionability: A framework to rank genomic alterations as targets for cancer precision…
RT @Annals_Oncology: The @myESMO Scale for Clinical Actionability: A framework to rank genomic alterations as targets for cancer precision…
RT @Annals_Oncology: The @myESMO Scale for Clinical Actionability: A framework to rank genomic alterations as targets for cancer precision…
RT @Annals_Oncology: The @myESMO Scale for Clinical Actionability: A framework to rank genomic alterations as targets for cancer precision…
RT @Annals_Oncology: The @myESMO Scale for Clinical Actionability: A framework to rank genomic alterations as targets for cancer precision…
RT @Annals_Oncology: The @myESMO Scale for Clinical Actionability: A framework to rank genomic alterations as targets for cancer precision…
RT @Annals_Oncology: The @myESMO Scale for Clinical Actionability: A framework to rank genomic alterations as targets for cancer precision…
RT @Annals_Oncology: The @myESMO Scale for Clinical Actionability: A framework to rank genomic alterations as targets for cancer precision…
RT @Annals_Oncology: The @myESMO Scale for Clinical Actionability: A framework to rank genomic alterations as targets for cancer precision…
RT @Annals_Oncology: The @myESMO Scale for Clinical Actionability: A framework to rank genomic alterations as targets for cancer precision…
RT @Annals_Oncology: The @myESMO Scale for Clinical Actionability: A framework to rank genomic alterations as targets for cancer precision…
RT @Annals_Oncology: The @myESMO Scale for Clinical Actionability: A framework to rank genomic alterations as targets for cancer precision…
RT @Annals_Oncology: The @myESMO Scale for Clinical Actionability: A framework to rank genomic alterations as targets for cancer precision…
RT @Annals_Oncology: The @myESMO Scale for Clinical Actionability: A framework to rank genomic alterations as targets for cancer precision…
The @myESMO Scale for Clinical Actionability: A framework to rank genomic alterations as targets for cancer precision medicine https://t.co/Zr506DO8Lb #precisionmedicine
RT @dave6408: A framework to rank genomic alterations as targets for cancer precision medicine | Annals of Oncology | https://t.co/i1Mgov9V…
RT @Annals_Oncology: Read the @myESMO Scale for Clinical Actionability of molecular Targets - A framework to rank genomic alterations as ta…
RT @cancermd: Excellent read (missed this over the summer months) measuring the true impact and clinical relevance of genomic alterations i…
RT @weoncologists: The #ESMO Scale of Clinical Actionability for molecular Targets (ESCAT) defines clinical evidence-based criteria to prio…
RT @mtmdphd: A framework to rank genomic alterations as targets for cancer #PrecisionMedicine : the @myESMO Scale for Clinical Actionabilit…
RT @cancermd: Excellent read (missed this over the summer months) measuring the true impact and clinical relevance of genomic alterations i…
RT @cancermd: Excellent read (missed this over the summer months) measuring the true impact and clinical relevance of genomic alterations i…
Excellent read (missed this over the summer months) measuring the true impact and clinical relevance of genomic alterations in Cancer https://t.co/6DZvE3X3n7
RT @mtmdphd: A framework to rank genomic alterations as targets for cancer #PrecisionMedicine : the @myESMO Scale for Clinical Actionabilit…
A framework to rank genomic alterations as targets for cancer #PrecisionMedicine : the @myESMO Scale for Clinical Actionability of molecular Targets (ESCAT) [Aug 21, 2018] Mateo et al. @Annals_Oncology https://t.co/woSwf15iFl HT @antonyruggeri